Want to see AU:ACL full AI Analyst Report?
ACL Stock Chart & Stats
AU$2.31
AU$0.04(1.73%)
At close: 4:00 PM EDT
AU$2.31
AU$0.04(1.73%)
Day’s Range― - ―
52-Week RangeAU$1.83 - AU$2.97
Previous CloseN/A
Volume426.92K
Average Volume (3M)867.30K
Market Cap
AU$443.92M
Enterprise ValueAU$828.11
Total Cash (Recent Filing)AU$23.14M
Total Debt (Recent Filing)AU$453.61M
Price to Earnings (P/E)16.0
Beta1.06
Next Earnings
Aug 26, 2026EPS Estimate
0.11Next Dividend Ex-DateN/A
Dividend Yield5.26%
Share Statistics
EPS (TTM)0.15
Shares Outstanding186,518,980
10 Day Avg. Volume799,589
30 Day Avg. Volume867,296
Financial Highlights & Ratios
PEG Ratio0.39
Price to Book (P/B)3.09
Price to Sales (P/S)0.71
P/FCF Ratio3.03
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$2.22Price Target Upside-4.11% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering2
EPS Forecast (FY)0.18
Revenue Forecast (FY)AU$764.44M
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationConsistent and improving cash generation (FCF +8.67%, OCF/NI 0.84, FCF/NI 0.95) provides durable funding for operations, dividends and capex without heavy equity issuance. High cash conversion reduces reliance on accrual earnings and strengthens resilience to revenue shocks.
Improved Gross MarginA materially higher gross margin (36.54%) indicates sustained cost efficiencies in laboratory operations and procurement. Better margins increase operating leverage potential, enabling reinvestment into specialized testing and network efficiency that supports long-term competitiveness.
High Return On EquityROE near 19% shows the company effectively turns shareholder capital into profits over time. When paired with strong cash conversion, this suggests durable operational productivity and capacity to generate shareholder returns if capital structure and margins are maintained.
Bears Say
High Financial LeverageSignificant leverage (debt/equity 1.69) raises refinancing and interest expense risk and limits strategic flexibility. In a reimbursement-sensitive industry, high debt amplifies exposure to volume or price shocks and constrains capacity to fund growth organically or via M&A.
Low Net Profit MarginA low net margin (4.37%) means limited residual profit after operating costs and financing. This constrains retained earnings for reinvestment, amplifies sensitivity to cost inflation or pricing pressure, and reduces the buffer against reimbursement or demand variability.
Modest Revenue GrowthVery modest top-line growth (1.79%) after earlier declines signals weak demand expansion or pricing pressure. For diagnostics, scale and volume drive margin improvement; sluggish revenue growth limits potential for operating leverage and long-term margin expansion.
Australian Clinical Labs Ltd News
ACL FAQ
What was Australian Clinical Labs Ltd’s price range in the past 12 months?
Australian Clinical Labs Ltd lowest share price was AU$1.83 and its highest was AU$2.97 in the past 12 months.
What is Australian Clinical Labs Ltd’s market cap?
Australian Clinical Labs Ltd’s market cap is AU$443.92M.
When is Australian Clinical Labs Ltd’s upcoming earnings report date?
Australian Clinical Labs Ltd’s upcoming earnings report date is Aug 26, 2026 which is in 19 days.
How were Australian Clinical Labs Ltd’s earnings last quarter?
Australian Clinical Labs Ltd released its earnings results on Feb 15, 2026. The company reported AU$0.067 earnings per share for the quarter, missing the consensus estimate of AU$0.073 by -AU$0.006.
Is Australian Clinical Labs Ltd overvalued?
According to Wall Street analysts Australian Clinical Labs Ltd’s price is currently Overvalued.
Does Australian Clinical Labs Ltd pay dividends?
Australian Clinical Labs Ltd pays a Semiannually dividend of AU$0.037 which represents an annual dividend yield of 5.26%. See more information on Australian Clinical Labs Ltd dividends here
What is Australian Clinical Labs Ltd’s EPS estimate?
Australian Clinical Labs Ltd’s EPS estimate is 0.11.
How many shares outstanding does Australian Clinical Labs Ltd have?
Australian Clinical Labs Ltd has 186,518,980 shares outstanding.
What happened to Australian Clinical Labs Ltd’s price movement after its last earnings report?
Australian Clinical Labs Ltd reported an EPS of AU$0.067 in its last earnings report, missing expectations of AU$0.073. Following the earnings report the stock price went up 6.768%.
Which hedge fund is a major shareholder of Australian Clinical Labs Ltd?
Currently, no hedge funds are holding shares in AU:ACL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Australian Clinical Labs Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Sell
Average Price Target:
AU$2.22 (-4.11% Downside)
AU$2.22 (-4.11% Downside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-28.73%
12-Months-Change
Fundamentals
Return on Equity
5.26%
Trailing 12-Months
Asset Growth
-3.86%
Trailing 12-Months
Company Description
Australian Clinical Labs Ltd
Australian Clinical Labs Limited operates across Australia, delivering a diverse range of diagnostic pathology services. The company's extensive portfolio encompasses standard examinations alongside advanced molecular genetics, including Harmony NIPT and initial trimester screenings, as well as genetic carrier screening. Furthermore, it provides detailed analyses in chemical, tissue (histopathology), and cellular (cytopathology) pathology; specialized tests for hematology, allergies, and immunology; and comprehensive serology and microbiology services. ACL also performs infectious molecular testing, cardiac diagnostic assessments, functional pathology, veterinary pathology, and commercial drug and alcohol screening. These essential services are supplied to both private and public hospitals throughout the nation. The company was founded in 2020 and maintains its primary operational base in Clayton, Australia.
ACL Stock 12 Month Forecast
Average Price Target
AU$2.22
▼(-4.11% Downside)
Technical Analysis
Healius Limited
―
BCAL Diagnostics Limited
―
Genetic Signatures Ltd.
―
Sonic Healthcare Limited
―
Integral Diagnostics Ltd.
―